Key result
Low-dose mRNA booster linked to smaller BNP increases than initial standard-dose vaccinations.
Why the study?
Does a low-dose mRNA COVID-19 booster vaccination reduce the risk of cardiac dysfunction in elderly patients with cardiovascular disorders compared to normal-dose vaccination?
Observational (n=76)
No
Does a low-dose mRNA COVID-19 booster vaccination reduce the risk of cardiac dysfunction in elderly patients with cardiovascular disorders compared to normal-dose vaccination?
A low-dose COVID-19 mRNA booster may mitigate the risk of sustained vaccine-induced cardiac deterioration in elderly patients with pre-existing cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Low-dose boosters were associated with attenuated BNP changes in elderly cardiac patients; hypothesis-generating and requires randomized confirmation before practice change.
We recently reported that sub-acute myocarditis occurred following the initial two doses of messenger RNA-based vaccination against coronavirus disease 2019 (0.3 mL Comirnaty®) in elderly Japanese patients with cardiac dysfunction. The present retrospective study of 76 patients revealed that myocarditis following the initial doses persisted for 12 months, was associated with low levels of neutralizing antibodies, and was ameliorated by reducing the third vaccine dose. Low neutralizing antibody levels (<220 U/mL) after the initial doses were an independent predictor of persistent clinical events, defined as death or marked changes in brain natriuretic peptide levels. When the third dose was reduced (0.1 mL), changes in brain natriuretic peptide levels were significantly smaller (p = 0.02, n = 25), no deaths occurred due to heart failure, and neutralizing antibody levels increased 41-fold (p < 0.001) compared with the initial doses. Reduced booster doses could facilitate the worldwide distribution of messenger RNA vaccines.
No takes yet. Share an insight, caveat, or question.
Miyazaki et al. (2023) conducted an observational in Cardiovascular disorders (n=76). Low-dose (0.1 mL) mRNA COVID-19 booster vaccination vs. Normal-dose first and second vaccinations was evaluated on Change in BNP ratio (p=0.02). Low-dose mRNA COVID-19 booster vaccination reduced the change in BNP ratio compared to initial normal-dose vaccinations.
Synapse has enriched 10 related papers. Consider them for comparative context: